Cargando…

Substantia nigral dopamine transporter uptake in dementia with Lewy bodies

Nigrostriatal dopaminergic degeneration is a pathological hallmark of dementia with Lewy bodies (DLB). To identify the subregional dopamine transporter (DAT) uptake patterns that improve the diagnostic accuracy of DLB, we analyzed N-(3-[(18)F] fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)-nortropa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Young-gun, Jeon, Seun, Baik, Kyoungwon, Kang, Sung Woo, Ye, Byoung Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256694/ https://www.ncbi.nlm.nih.gov/pubmed/37296236 http://dx.doi.org/10.1038/s41531-023-00534-9

Ejemplares similares

Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies
por: Kang, Sung Woo, et al.
Publicado: (2021)

Neuropsychological Comparison of Patients With Alzheimer’s Disease and Dementia With Lewy Bodies
por: Kang, Sungwoo, et al.
Publicado: (2023)

Re: Comments on “Neuropsychological Comparison of Patients With Alzheimer’s Disease and Dementia With Lewy Bodies”: Author Response
por: Kang, Sungwoo, et al.
Publicado: (2023)

Distinct amyloid-dependent patterns of nigra dopamine depletion in Lewy body diseases
por: Baik, Kyoungwon, et al.
Publicado: (2023)

Analysis of the Substantia Innominata Volume in Patients with Parkinson’s Disease with Dementia, Dementia with Lewy Bodies, and Alzheimer’s Disease
por: Kim, Hee Jin, et al.
Publicado: (2011)

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Substantia nigra micro-haemorrhage causing ipsilateral unilateral Parkinsonism and abnormal dopamine transporter scan uptake
por: Ghoneim, Aliaa, et al.
Publicado: (2020)

Structural connectivity networks in Alzheimer’s disease and Lewy body disease
por: Baik, Kyoungwon, et al.
Publicado: (2021)

Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study
por: Park, So Hee, et al.
Publicado: (2021)

Comparison Between (18)F-Florapronol and (18)F-Florbetaben Imaging in Patients With Cognitive Impairment
por: Baik, Kyoungwon, et al.
Publicado: (2023)

The role of (123)I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies
por: Antonini, Angelo
Publicado: (2007)

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Implication of EEG theta/alpha and theta/beta ratio in Alzheimer’s and Lewy body disease
por: Baik, Kyoungwon, et al.
Publicado: (2022)

Structural grey matter changes in the substantia innominata in Alzheimer's disease and dementia with Lewy bodies: a DARTEL‐VBM study
por: Colloby, Sean J., et al.
Publicado: (2016)

Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease
por: Lee, Young-gun, et al.
Publicado: (2022)

Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014)

Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients
por: Fernández, Belén, et al.
Publicado: (2017)

Metric magnetic resonance imaging analysis reveals pronounced substantia-innominata atrophy in dementia with Lewy bodies with a psychiatric onset
por: Hansen, Niels, et al.
Publicado: (2022)

Dementia with Lewy bodies
por: McKeith, Ian
Publicado: (2004)

Lower (123)I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies
por: Joling, Merijn, et al.
Publicado: (2018)

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy
por: Engeln, Michel, et al.
Publicado: (2016)

Dopaminergic Presynaptic Modulation of Nigral Afferents: Its Role in the Generation of Recurrent Bursting in Substantia Nigra Pars Reticulata Neurons
por: de Jesús Aceves, José, et al.
Publicado: (2011)

Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson’s disease
por: Chen, Yupin, et al.
Publicado: (2015)

Neuroimaging in Lewy body dementia
por: Yousaf, Tayyabah, et al.
Publicado: (2018)

Microbleeds in dementia with Lewy bodies
por: Donaghy, Paul C., et al.
Publicado: (2020)

Advances in dementia with Lewy bodies
por: Armstrong, Melissa J.
Publicado: (2021)

Neuroimaging in Dementia With Lewy Bodies
por: Saha, Abhishikta, et al.
Publicado: (2021)

HIV Dementia with a Decreased Cardiac (123)I-metaiodobenzylguanidine Uptake Masquerading as Dementia with Lewy Bodies
por: Kurihara, Masanori, et al.
Publicado: (2018)

Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease
por: Simunovic, Filip, et al.
Publicado: (2010)

Subcellular Patch-clamp Recordings from the Somatodendritic Domain of Nigral Dopamine Neurons
por: Engel, Dominique
Publicado: (2016)

Neuroprotective potential of ocimum sanctum (Linn) leaf extract in preventing and attenuating stress induced substantia nigral neuronal damage in rats
por: Rodrigues, Vincent, et al.
Publicado: (2022)

Motor Dysfunction Questionnaire and Dopamine Transporter Imaging Composite Scale Improve Differentiating Dementia With Lewy Bodies From Alzheimer's Disease With Motor Dysfunction
por: Chiu, Pai-Yi, et al.
Publicado: (2021)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies
por: Garcia-Esparcia, Paula, et al.
Publicado: (2018)

Neuroimaging characteristics of dementia with Lewy bodies
por: Mak, Elijah, et al.
Publicado: (2014)

Comprehensive treatment of dementia with Lewy bodies
por: Boot, Brendon P
Publicado: (2015)

Neurophysiological biomarkers for Lewy body dementias
por: Cromarty, Ruth A., et al.
Publicado: (2016)

Exome sequencing in dementia with Lewy bodies
por: Keogh, M J, et al.
Publicado: (2016)

Clinical prevalence of Lewy body dementia
por: Kane, Joseph P. M., et al.
Publicado: (2018)

Dementia with Lewy bodies: an update and outlook
por: Outeiro, Tiago Fleming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s1eec83a0pu60lm8r5bs5tpt77